Denali Therapeutics (DNLI)
Denali Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
15.5M
Short interest
settlement 2026-09-30
7.6
Days to cover
-4.3 days vs prior
44.3%
Short share of volume
2026-10-09
39,910
Fails to deliver
settlement 2026-09-10
Thu 5 Nov
Next earnings
estimated date
-$435K
Insider flow, 90 days
0 buys, 5 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in DNLI is 15,463,975 shares, down 1,178,387 shares over the last month. Over the last 48 readings it ranged from 7,098,359 shares (15 November 2024) to 17,959,465 shares (14 August 2026). At the reported average volume of 2.0M shares a day that is 7.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/dnli" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 15,463,975 | -9.8% | 2,023,714 | 7.64 |
| 2026-09-15 | 17,139,415 | +3.0% | 1,431,794 | 11.97 |
| 2026-08-31 | 16,642,362 | -7.3% | 951,216 | 17.50 |
| 2026-08-14 | 17,959,465 | +3.0% | 1,446,971 | 12.41 |
| 2026-07-31 | 17,434,654 | +8.7% | 1,438,878 | 12.12 |
| 2026-07-15 | 16,035,916 | +0.5% | 1,910,758 | 8.39 |
| 2026-06-30 | 15,949,089 | +3.5% | 2,295,382 | 6.95 |
| 2026-06-15 | 15,407,744 | +2.8% | 1,827,145 | 8.43 |
| 2026-05-29 | 14,990,471 | +6.9% | 1,870,118 | 8.02 |
| 2026-05-15 | 14,026,925 | -5.3% | 1,867,525 | 7.51 |
| 2026-04-30 | 14,813,936 | -3.1% | 1,488,830 | 9.95 |
| 2026-04-15 | 15,284,401 | -0.9% | 1,384,899 | 11.04 |
| 2026-03-31 | 15,421,152 | +8.2% | 2,313,194 | 6.67 |
| 2026-03-13 | 14,258,580 | -0.4% | 1,496,161 | 9.53 |
| 2026-02-27 | 14,319,419 | +5.3% | 1,586,528 | 9.03 |
| 2026-02-13 | 13,594,971 | +0.3% | 1,560,915 | 8.71 |
| 2026-01-30 | 13,558,718 | -8.8% | 1,931,940 | 7.02 |
| 2026-01-15 | 14,858,586 | +2.0% | 1,535,667 | 9.68 |
| 2025-12-31 | 14,560,677 | +11.2% | 1,168,804 | 12.46 |
| 2025-12-15 | 13,092,563 | +0.9% | 2,129,587 | 6.15 |
| 2025-11-28 | 12,977,218 | -7.4% | 1,291,586 | 10.05 |
| 2025-11-14 | 14,017,386 | +6.9% | 1,547,313 | 9.06 |
| 2025-10-31 | 13,110,288 | -9.8% | 1,481,293 | 8.85 |
| 2025-10-15 | 14,527,782 | +2.7% | 1,705,495 | 8.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of DNLI volume is 44.3%, up 2.4 points over the last five sessions. Over the last 30 readings it ranged from 30.3% (2 September 2026) to 76.7% (6 October 2026). The latest reading is 8.4 points below the 30-session average of 52.7%, on 476K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 211K | 476K | 44.3% | 22 |
| 2026-10-08 | 251K | 495K | 50.8% | 1 |
| 2026-10-07 | 248K | 459K | 54.2% | 2,766 |
| 2026-10-06 | 912K | 1.2M | 76.7% | 998 |
| 2026-10-05 | 310K | 550K | 56.4% | 0 |
| 2026-10-02 | 257K | 613K | 41.9% | 0 |
| 2026-10-01 | 389K | 652K | 59.7% | 0 |
| 2026-09-30 | 367K | 647K | 56.8% | 0 |
| 2026-09-29 | 217K | 486K | 44.6% | 0 |
| 2026-09-28 | 468K | 950K | 49.2% | 1 |
| 2026-09-25 | 263K | 514K | 51.2% | 225 |
| 2026-09-24 | 538K | 977K | 55.1% | 0 |
| 2026-09-23 | 404K | 635K | 63.7% | 1,533 |
| 2026-09-22 | 469K | 852K | 55.0% | 7 |
| 2026-09-21 | 307K | 988K | 31.0% | 100 |
| 2026-09-18 | 231K | 567K | 40.7% | 0 |
| 2026-09-17 | 231K | 505K | 45.8% | 0 |
| 2026-09-16 | 338K | 661K | 51.1% | 0 |
| 2026-09-15 | 617K | 812K | 76.0% | 32 |
| 2026-09-14 | 180K | 354K | 50.8% | 0 |
| 2026-09-11 | 308K | 448K | 68.7% | 0 |
| 2026-09-10 | 179K | 297K | 60.2% | 0 |
| 2026-09-09 | 346K | 819K | 42.3% | 0 |
| 2026-09-08 | 229K | 600K | 38.1% | 0 |
| 2026-09-04 | 171K | 283K | 60.6% | 382 |
| 2026-09-03 | 272K | 586K | 46.4% | 2,075 |
| 2026-09-02 | 216K | 713K | 30.3% | 0 |
| 2026-09-01 | 249K | 492K | 50.6% | 11 |
| 2026-08-31 | 128K | 226K | 56.6% | 74 |
| 2026-08-28 | 173K | 238K | 72.5% | 69 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 10 September 2026, the fails-to-deliver balance in DNLI is 39,910 shares, up 39,234 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (16 April 2026) to 179,418 shares (27 May 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-10 | 39,910 | $21.57 | $861K |
| 2026-09-08 | 676 | $22.28 | $15K |
| 2026-09-04 | 5,459 | $22.80 | $124K |
| 2026-09-03 | 8,776 | $22.85 | $201K |
| 2026-08-25 | 400 | $24.20 | $10K |
| 2026-08-24 | 3,095 | $24.92 | $77K |
| 2026-08-21 | 3,852 | $24.95 | $96K |
| 2026-08-18 | 31 | $24.35 | $755 |
| 2026-08-07 | 4,921 | $24.73 | $122K |
| 2026-07-16 | 40 | $23.02 | $921 |
| 2026-07-13 | 92 | $25.68 | $2K |
| 2026-07-02 | 439 | $25.98 | $11K |
| 2026-07-01 | 60 | $25.72 | $2K |
| 2026-06-30 | 191 | $25.89 | $5K |
| 2026-06-26 | 28 | $24.73 | $692 |
| 2026-06-24 | 7,431 | $24.77 | $184K |
| 2026-06-22 | 315 | $23.31 | $7K |
| 2026-06-15 | 106 | $21.66 | $2K |
| 2026-06-11 | 49 | $20.61 | $1K |
| 2026-06-10 | 184 | $20.79 | $4K |
| 2026-06-08 | 30,328 | $19.52 | $592K |
| 2026-06-03 | 1,327 | $19.35 | $26K |
| 2026-06-02 | 2,722 | $20.41 | $56K |
| 2026-05-27 | 179,418 | $19.38 | $3.5M |
| 2026-05-18 | 217 | $18.62 | $4K |
| 2026-05-08 | 8 | $19.71 | $158 |
| 2026-05-04 | 411 | $18.30 | $8K |
| 2026-04-30 | 12 | $18.60 | $223 |
| 2026-04-16 | 1 | $21.68 | $22 |
| 2026-04-15 | 59 | $20.16 | $1K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at DNLI reported 5 open-market sells worth $435K in the last 90 days and no open-market buys. Latest filing: Chin Peter Scott (Chief Medical Officer) on 2026-09-04.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Chin Peter Scott | Chief Medical Officer | Sell | 2K | $22.29 | $37K | 205K |
| 2026-09-02 | Thornberry Nancy | Director | Sell | 615 | $23.74 | $15K | 20K |
| 2026-09-02 | Thornberry Nancy | Director | Sell | 11K | $22.85 | $247K | 20K |
| 2026-09-01 | Schuth Alexander O. | COFO and Secretary | Sell | 3K | $23.44 | $65K | 279K |
| 2026-08-12 | Watts Ryan J. | President and CEO | Gift | 32K | $0.00 | $0 | 2.1M |
| 2026-08-11 | Schuth Alexander O. | COFO and Secretary | Sell | 3K | $25.07 | $72K | 282K |
| 2026-06-03 | Baker Brothers Life Sciences LP | Director | Grant | 6K | $0.00 | $0 | 343K |
| 2026-06-03 | Van Hauwermeiren Timothy | Director | Grant | 6K | $0.00 | $0 | 17K |
| 2026-06-03 | Thornberry Nancy | Director | Grant | 6K | $0.00 | $0 | 31K |
| 2026-06-03 | Krognes Steve E. | Director | Grant | 6K | $0.00 | $0 | 38K |
| 2026-06-03 | Schenkein David P | Director | Grant | 6K | $0.00 | $0 | 22K |
| 2026-06-03 | Klein Peter S | Director | Grant | 6K | $0.00 | $0 | 34K |
| 2026-06-03 | FLATLEY JAY T | Director | Grant | 6K | $0.00 | $0 | 23K |
| 2026-06-03 | Cook Jennifer E. | Director | Grant | 6K | $0.00 | $0 | 32K |
| 2026-06-03 | BAKER BROS. ADVISORS LP | Director | Grant | 6K | $0.00 | $0 | 343K |
| 2026-01-06 | Schuth Alexander O. | COFO and Secretary | Sell | 17K | $16.50 | $284K | 283K |
| 2026-01-06 | Watts Ryan J. | President and CEO | Sell | 35K | $16.50 | $581K | 297K |
| 2026-01-03 | Schuth Alexander O. | COFO and Secretary | Grant | 58K | $0.00 | $0 | 300K |
| 2026-01-03 | Watts Ryan J. | President and CEO | Grant | 79K | $0.00 | $0 | 332K |
| 2025-11-04 | Van Hauwermeiren Timothy | Director | Grant | 11K | $0.00 | $0 | 11K |
| 2025-09-03 | Watts Ryan J. | President and CEO | Gift | 50K | $0.00 | $0 | 2.2M |
| 2025-08-13 | Ho Carole | Chief Medical Officer | Sell | 806 | $14.64 | $12K | 217K |
| 2025-08-12 | Schuth Alexander O. | COFO and Secretary | Sell | 3K | $13.58 | $40K | 242K |
| 2025-08-12 | Ho Carole | Chief Medical Officer | Sell | 3K | $13.58 | $40K | 217K |
| 2025-08-05 | Ho Carole | Chief Medical Officer | Option exercise | 45K | $0.68 | $30K | 220K |
| 2025-07-09 | Watts Ryan J. | President and CEO | Sell | 495K | $15.00 | $7.4M | 253K |
| 2025-07-09 | Watts Ryan J. | President and CEO | Option exercise | 40K | $5.28 | $211K | 748K |
| 2025-07-09 | Watts Ryan J. | President and CEO | Option exercise | 455K | $0.68 | $310K | 708K |
| 2025-06-03 | BAKER BROS. ADVISORS LP | Director | Grant | 11K | $0.00 | $0 | 3.4M |
| 2025-06-03 | Tessier-Lavigne Marc | Director | Grant | 6K | $0.00 | $0 | 1.9M |
| 2025-06-03 | Thornberry Nancy | Director | Grant | 6K | $0.00 | $0 | 25K |
| 2025-06-03 | Schenkein David P | Director | Grant | 6K | $0.00 | $0 | 15K |
| 2025-06-03 | Krognes Steve E. | Director | Grant | 6K | $0.00 | $0 | 32K |
| 2025-06-03 | Klein Peter S | Director | Grant | 6K | $0.00 | $0 | 28K |
| 2025-06-03 | FLATLEY JAY T | Director | Grant | 6K | $0.00 | $0 | 16K |
| 2025-06-03 | Cook Jennifer E. | Director | Grant | 6K | $0.00 | $0 | 26K |
| 2025-06-03 | BAKER BROS. ADVISORS LP | Director | Grant | 11K | $0.00 | $0 | 337K |
| 2025-01-07 | Krognes Steve E. | Director | Sell | 3K | $20.81 | $69K | 26K |
| 2025-01-07 | Watts Ryan J. | President and CEO | Sell | 8K | $20.81 | $159K | 253K |
| 2025-01-07 | Schuth Alexander O. | COFO and Secretary | Sell | 3K | $20.81 | $60K | 244K |
| 2025-01-07 | Ho Carole | Chief Medical Officer | Sell | 3K | $20.81 | $60K | 176K |
| 2025-01-06 | Watts Ryan J. | President and CEO | Sell | 29K | $20.22 | $592K | 261K |
| 2025-01-06 | Schuth Alexander O. | COFO and Secretary | Sell | 12K | $20.22 | $248K | 247K |
| 2025-01-06 | Ho Carole | Chief Medical Officer | Sell | 12K | $20.22 | $248K | 179K |
| 2025-01-03 | Ho Carole | Chief Medical Officer | Grant | 54K | $0.00 | $0 | 191K |
| 2025-01-03 | Schuth Alexander O. | COFO and Secretary | Grant | 54K | $0.00 | $0 | 259K |
| 2025-01-03 | Watts Ryan J. | President and CEO | Grant | 54K | $0.00 | $0 | 290K |
| 2025-01-02 | SATO VICKI L | Director | Sell | 3K | $20.91 | $64K | 108K |
| 2024-12-31 | Krognes Steve E. | Director | Sell | 30K | $20.25 | $608K | 29K |
| 2024-12-27 | Schuth Alexander O. | COFO and Secretary | Option exercise | 7K | $5.28 | $35K | 205K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON9 Form 144 notices on file for DNLI worth $8.8M at the prices reported; 2 in the last 90 days worth $332K. Latest: NANCY THORNBERRY filed on 2026-09-02 to sell 11,439 shares ($266K) from 2026-09-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-02 | NANCY THORNBERRYDirector | 11K | $266K | 0.007% | 2026-09-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-01 | ALEXANDER SCHUTHOfficer | 3K | $66K | 0.005% | 2026-09-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-05 | CAROLE HOFormer Affiliate | 39K | $801K | 0.027% | 2026-02-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-04 | CAROLE HOFormer Affiliate | 150K | $3.2M | 0.102% | 2026-02-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-03 | CAROLE HOFormer Affiliate | 150K | $3.3M | 0.102% | 2026-02-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-06 | Ho CaroleConsultant | 17K | $284K | 0.011% | 2026-01-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-06 | Schuth Alexander O.Officer | 17K | $284K | 0.011% | 2026-01-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-06 | Watts Ryan J.Director, Officer | 35K | $581K | 0.023% | 2026-01-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | CAROLE HOOfficer | 2K | $36K | 0.001% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of DNLI in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 10.2% of the class (16,178,963 shares), filed 2026-07-08 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-04 | 13G/Ano. 8 | BAILLIE GIFFORD & COinvestment adviser | 12.0M | 7.5% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 1 | T. Rowe Price Investment Management, Inc.investment adviser | 16.2M | 10.2% | 2026-06-30 |
| 2026-05-06 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 6.7M | 4.2% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 3 | FMR LLCparent holding company | 6.7M | 4.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding DNLI at their latest 13F. JSON4 of the 30 tracked managers held DNLI at their latest 13F, $102.8M in total at quarter-end prices. Fisher Asset Management is the largest at $62.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Fisher Asset Management | 2026-06-30 | 2.4M | $62.1M | 0.02% | -23K |
| Millennium Management | 2026-06-30 | 1.1M | $29.0M | 0.01% | -132K |
| AQR Capital Management | 2026-06-30 | 388K | $10.0M | 0.00% | +286K |
| Citadel Advisors | 2026-06-30 | 67K | $1.7M | 0.00% | -114K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Denali Therapeutics reported revenue of $3.6M, and net loss of $127.6M (-0.68 diluted EPS). In FY 2025 it generated -$412.6M of operating cash flow.
- Cash
- $201.5M
- Equity
- $835.2M
- Total assets
- $1.16B
- Shares outstanding
- 159,847,403
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $3.6M | -$127.6M | -3539.2% | -0.68 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$128.4M | n/a | -0.69 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$128.5M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$126.9M | n/a | -0.74 |
| Q2 FY 2025 | 2025-06-30 | $0 | -$124.1M | n/a | -0.72 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$133.0M | n/a | -0.78 |
| Q4 FY 2024derived | 2024-12-31 | $0 | -$114.8M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $0 | -$107.2M | n/a | -0.63 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | -$512.5M | -$412.6M | $9.5M | n/a | n/a |
| FY 2024 | 2024-12-31 | $0 | -$422.8M | -$347.7M | $15.9M | n/a | n/a |
| FY 2023 | 2023-12-31 | $330.5M | -$145.2M | -$358.0M | $12.9M | n/a | n/a |
| FY 2022 | 2022-12-31 | $105.1M | -$326.0M | -$244.7M | $17.8M | n/a | n/a |
| FY 2021 | 2021-12-31 | $48.7M | -$290.6M | -$211.4M | $8.5M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Denali Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Denali Therapeutics (DNLI), SEC CIK 1714899, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-10.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-04.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-02-26.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 1714899Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- MRNAModerna
- TWSTTwist Bioscience
- ADPTAdaptive Biotechnologies
- NVAXNovavax
- RXRXRecursion Pharmaceuticals
- DNAGinkgo Bioworks Holdings
- PCVXVaxcyte
- NBIXNeurocrine Biosciences
- VIRVir Biotechnology
- EXELExelixis
- RVMDRevolution Medicines
- GILDGilead Sciences
- HALOHalozyme Therapeutics
- KYMRKymera Therapeutics
- AMGNAmgen
- KRYSKrystal Biotech
- RGENRepligen
- VCELVericel
- BIIBBiogen
- CRSPCRISPR Therapeutics
- KODKodiak Sciences
- BDTXBlack Diamond Therapeutics
- TECHBio-Techne
- BEAMBeam Therapeutics
Datasets
Frequently Asked Questions
How much of DNLI is sold short?
What is DNLI's daily short volume?
Does DNLI have fails to deliver?
Are DNLI insiders buying or selling?
Have DNLI insiders filed to sell?
Who owns 5% or more of DNLI?
What did DNLI report last quarter?
Which tracked 13F managers own DNLI?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.